Skip to main content
Equibles

AZN · Astrazeneca PLC

Track AZN — free

Use AZN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AZN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$156.90 -0.80 (-0.51%)
Rebalance outlook locked
Market Cap
$254.67B
Shares
1.55B
Volume · Oct 2 2.65M Avg daily vol (3M) 3.4M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$157.70 Open$160.77 Day$157.54–161.33 52W close$155.62–209.48 Avg vol 30d3.1M Short int2.1M · 0.1% float · 1.0d Short vol46% Last earningsJul 27, 2026 DataJan 2020–Oct 2026

Up next

Next earnings call
Oct 28, 2026 Est · unconfirmed · in 4 wks
Q1 2026 earnings call transcript
call held Apr 29, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$61.37B
Trailing 12 months
Net income (TTM)
$10.45B
Trailing 12 months
Revenue growth YoY
+6.4%
Year over year
Operating margin
22.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
4.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$22.11B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Very Bullish Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 16.4 · calm Equity put/call 0.57
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −13%
below
Price vs 50-day avg −4%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 4%
near low
Momentum
relative strength
Very Weak
1-month return −2%
trailing
6-month return −23%
trailing
YTD return −14%
this year
Relative strength −35%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $164 › 200d $182 — 200d above 50d
Institutional flow Accumulating
6 of 1,483 funds reported for Sep 30 · net +54 sh shares
Insider flow Accumulating
Net +$3.2K over 90 days · 0% sells
Short interest Falling
0.13% of float · ▼ -27.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,483 holders — near 3-yr high, broad support
Squeeze score 28
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 27%
annualized · 1-yr
Max drawdown −26%
past year
ATR 2.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Mar 31, 2026
full year 2026
Milestone payments Initiated $2.5B
peak year (COPD alone)
Peak sales $3B – $5B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−13% Bearish
Price vs 50-day avg
−4% Neutral
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
4% Bearish
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $164 › 200d $182 — 200d above 50d
Institutional flow Accumulating
6 of 1,483 funds reported for Sep 30 · net +54 sh shares
Insider flow Accumulating
Net +$3.2K over 90 days · 0% sells
Short interest Falling
0.13% of float · ▼ -27.9% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,483 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $156 Now $158 · 4% Range high $209
vs 200-day avg -13% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AZN
Astrazeneca PLC
this stock
$254.67B — — — 0.1%
LLY
ELI LILLY & Co
 $1.11T +7.0% +44.7% 39.7 0.8%
JNJ
Johnson & Johnson
 $653.61B +25.0% +6.0% 31.5 0.9%
ABBV
AbbVie Inc.
 $466.80B +13.8% +8.6% 74.6 1.1%
MRK
Merck & Co., Inc.
 $367.07B +36.6% +1.3% 119.0 1.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
1,482
% held
52.4%
Reported
6 of 1,483
Top holder
INVESTOR AB
Held Float
View
Held by Funds
Fund positions
151
View
Short & Settlement
Short Interest Falling
Shares short
2.1M
Days to cover
1.0d
Change
-807.4K sh
View
Short Volume
Short vol %
46%
As of
Oct 1, 2026
Short Total
View
Fails to Deliver
FTD shares
3.9K
Value
$629.3K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
47.7%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$3.2K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Nov 19, 2025
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 2, 2026
This year
91
View
Proposed Sales
Value
$1.3M
Shares
15.0K
Filed
Nov 12, 2025
View
Earnings & Events
Webcasts
Last webcast
Jul 27, 2026
View

Performance

5D 20D 120D MTD YTD
AZN -4.2% -2.4% -22.7% -2.3% -14.2%
SPY -0.4% -0.2% +12.4% +0.2% +12.0%
vs SPY -3.8% -2.3% -35.2% -2.5% -26.3%
Key facts CIK 901832 CUSIP G0593M107 13F (30d) 29 filings 24 filers Visit website Investor relations